BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and
markets products in the field of regenerative medicine, today announced
that Chief Executive Officer Michael D. West, PhD will present at the Scale-Up
and Manufacturing of Cell-Based Therapies II conference in San
Diego, California on Monday, January 21, 2013. Dr. West’s presentation
titled “hES-Derived Clonal Embryonic Progenitor Cell Lines: A Novel
Point of Scalability” is scheduled for 4:30 pm PST. Dr. West will
describe BioTime’s novel and proprietary PureStemTM
technology which allows the industrial scale-up of over 200 different
human cell types in a highly purified state from human embryonic stem
cells. In addition, Dr. West will present new data recently generated
using the technology. The presentation will be made available on
BioTime's website at www.biotimeinc.com.
The second annual conference on Scale-Up and Manufacturing of Cell-Based
Therapies is scheduled for January 21-23, 2013. It is sponsored by
Engineering Conferences International, a not-for-profit global
engineering conferences program, originally established in 1962, that
provides opportunities for the exploration of problems and issues of
concern to engineers and scientists from many disciplines. This
conference will focus on process development, scale-up, and
manufacturing of cell-based therapies and will bring academicians,
clinicians, industry leaders, and regulators from all over the world
together to discuss the most critical scientific and engineering
challenges in this field.
Pluripotent stem cells such as human embryonic stem and induced
pluripotent stem cells have attracted a great deal of attention in the
research community and pharmaceutical industry as a potential means of
manufacturing a wide array of novel cell-based therapies where cells, as
opposed to drugs, are introduced into the body to regenerate tissue
function. However, since these new and powerful stem cells become all of
the cell types in the human body, methods to reliably scale up only
particular and desired cell types from the stem cells without
contamination from other undesired cell types are of significant
interest. BioTime’s solution is a proprietary PureStemTM
technology that generates monoclonal lines of over 200 defined human
embryonic progenitor cell types from human embryonic stem cells. This
technology allows desired cell types such as cartilage, bone, tendon,
vascular cells, and many other cell types to be manufactured on an
industrial scale while maintaining a high degree of purity and certainty
of cellular identity.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is enhanced
through subsidiaries focused on specific fields of application. BioTime
develops and markets research products in the fields of stem cells and
regenerative medicine, including a wide array of proprietary PureStem™
cell lines, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly
known as HyStem®-Rx), a biocompatible,
implantable hyaluronan and collagen-based matrix for cell delivery in
human clinical applications. BioTime's therapeutic product development
strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical
need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic applications
of stem cells to treat orthopedic diseases and injuries. Another
subsidiary, OncoCyte Corporation, focuses on the diagnostic and
therapeutic applications of stem cell technology in cancer, including
the diagnostic product PanC-Dx™ currently being developed for the
detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent
stem cell technology to reverse the developmental aging of human cells
to treat cardiovascular and blood cell diseases. BioTime's subsidiary
LifeMap Sciences, Inc. markets GeneCards®, the leading
human gene database, and is developing an integrated database suite to
complement GeneCards® that will also include the LifeMap
Discovery™ database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database.
LifeMap will also market BioTime research products. BioTime Acquisition
Corporation (“BAC”) is a subsidiary being used to acquire the stem cell
assets of Geron Corporation, including patents and other intellectual
property, biological materials, reagents and equipment. BioTime's lead
product, Hextend®, is a blood plasma volume expander
manufactured and distributed in the U.S. by Hospira, Inc. and in South
Korea by CJ CheilJedang Corporation under exclusive licensing
agreements. Additional information about BioTime can be found on the web
at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts